EQ — Equillium, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1746466 ·
Last close
$1.44
Market Cap
$91.31M
52W High
$3.54
52W Low
$0.76
ADV30
618,154
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -5,155,000 | -4,693,000 | 58,666,000 | 57,164,000 | 2,650,000 |
| Mar 2026 | 0 | — | -5,610,000 | -5,311,000 | 63,083,000 | 61,322,000 | 3,596,000 |
| Dec 2025 | 0 | — | -3,962,000 | -3,775,000 | 31,887,000 | 30,277,000 | 3,290,000 |
| Sep 2025 | 0 | — | -4,575,000 | -4,230,000 | 34,506,000 | 33,120,000 | 3,567,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,878,000
Investing CF
$-35,000
Financing CF
$65,682,000
CapEx
$-55,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.32
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-221,516,000
Inventory
—
Receivables
$108,000
ST Investments
$0
EBIT TTM
$-20,375,000
Pretax Income TTM
$-19,055,000
Interest Exp TTM
$0
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -23,634,000 | -22,398,000 | 31,887,000 | 3,290,000 | 28,597,000 | -22,746,000 |
| Dec 2024 | 41,095,000 | -8,269,000 | -8,067,000 | 25,604,000 | 6,543,000 | 19,061,000 | -19,026,000 |
| Dec 2023 | 36,084,000 | -14,522,000 | -13,335,000 | 50,530,000 | 27,957,000 | 22,573,000 | -21,783,000 |
| Dec 2022 | 15,759,000 | -39,027,000 | -62,428,000 | 78,421,000 | 46,479,000 | 31,942,000 | -8,733,000 |
TTM Snapshot
Revenues TTM
$969,000
NetIncome TTM
$-19,055,000
OpCashFlow TTM
—
Assets (Latest)
$63,083,000
Forward EPS
$-0.23
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $1.41 · call volume: 20 · put volume: 1
Expected Move to 2026-10-16:
±$1.10
(78.01%) —
implied range
$0.31 –
$2.51
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RANI | Rani Therapeutics Holdings, Inc. | $91.42M | $0.79 | — |
| RLYB | Rallybio Corp | $90.23M | $16.99 | — |
| OKUR | OnKure Therapeutics, Inc. | $93.14M | $2.30 | — |
| MIST | Milestone Pharmaceuticals Inc. | $88.66M | $0.71 | — |
| CTOR | CITIUS ONCOLOGY, INC. | $88.31M | $0.83 | — |
News headlines (Yahoo Finance, 1h cache)
Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
2026-10-06 20:05 · Yahoo
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
2026-10-05 20:05 · Yahoo
Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504
2026-09-27 22:01 · Yahoo
Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum
2026-09-16 12:30 · Yahoo
Equillium to Participate in Upcoming Investor Conferences
2026-09-02 12:30 · Yahoo
Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-08-13 20:05 · Yahoo
Analysts Grow More Confident In Equillium’s (EQ) Lead Asset EQ504
2026-06-10 17:45 · Yahoo
Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1
2026-05-29 15:03 · Yahoo
Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis
2026-05-20 20:05 · Yahoo
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights
2026-05-13 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.